US Employers Reassess GLP-1 Obesity Drug Coverage Amid Rising Demand
Published on: June 12, 2026, 2:27 a.m. | Source: Devdiscourse
A number of U.S. employers plan to eliminate coverage for GLP-1 obesity drugs, like Novo Nordisk's Wegovy, in 2027. This decision counters savings from lower drug prices amid increasing usage of these medications. The move could affect access to these drugs for weight loss through employer-sponsored health plans.
